David Sinclair Longevity Hypothesized Full Protocol

Who Is David Sinclair and Why Does His Protocol Matter?

David Sinclair is a professor of genetics at Harvard Medical School and co-director of the Paul F. Glenn Center for Biology of Aging Research. His 2019 book "Lifespan: Why We Age and Why We Don't Have To" introduced millions of readers to sirtuin biology, NAD+ metabolism, and the idea that aging is a treatable disease. He has discussed his personal regimen in more than a dozen public forums.

His self-reported protocol carries weight not because it constitutes medical advice, but because Sinclair is the principal investigator behind peer-reviewed sirtuin and NAD+ research that has been published in leading journals including Cell and Nature. The compounds he takes are, in most cases, the same ones his lab has studied in animal models.

The Information Theory of Aging

Sinclair's core framework holds that aging results from a loss of epigenetic information, not simply DNA mutations. Sirtuins, a family of NAD+-dependent deacetylases, function as epigenetic regulators. When NAD+ levels fall, as they do with age, sirtuin activity declines and the epigenome destabilizes. This model is outlined in his 2013 paper in Cell alongside Leonard Guarente and others, which described sirtuins as potential "longevity genes" activated by caloric restriction [1].

Why "Hypothesized Protocol"?

The word "hypothesized" matters here. Sinclair has been transparent that he is running an n=1 experiment on himself. His biological age scores using epigenetic clocks have been discussed publicly but have not been peer-reviewed. Nothing in this article should be read as a clinical recommendation.

NMN: The Core NAD+ Precursor

Sinclair has consistently stated he takes 1,000 mg of nicotinamide mononucleotide (NMN) each morning. NMN is a direct precursor to NAD+ and enters cells via a dedicated transporter, Slc12a8, identified in a 2019 Cell Metabolism paper [2]. NAD+ levels in human tissue decline roughly 50% between age 40 and 60 [3].

What the Human Trials Show

The clinical evidence for NMN in humans is early but growing. A 2021 randomized, placebo-controlled trial published in Science (Yoshino et al., N=25 postmenopausal women with prediabetes) found that 250 mg/day oral NMN for 10 weeks increased muscle NAD+ metabolome and improved insulin signaling in skeletal muscle, though it did not change insulin sensitivity measured by the gold-standard hyperinsulinemic-euglycemic clamp [4]. A separate 2022 trial (N=80 middle-aged adults) published in GeroScience found 300 mg/day NMN for 60 days raised blood NAD+ levels and improved muscle strength and performance on a 6-minute walk test [5].

Neither trial used Sinclair's 1,000 mg dose. Whether higher doses produce proportionally stronger effects in healthy humans remains unknown.

Timing With Resveratrol

Sinclair dissolves resveratrol in yogurt alongside NMN each morning. He has explained in the Lex Fridman podcast (episode 189, 2022) that fat-soluble resveratrol absorbs poorly without a lipid vehicle. Resveratrol activates SIRT1 in vitro, but oral bioavailability is notoriously low. A pharmacokinetic study in the British Journal of Nutrition (N=40) found that co-ingestion with a high-fat meal increased peak plasma resveratrol concentration by 5-fold compared with a fasted state [6].

Resveratrol: SIRT1 Activator or Overhyped Polyphenol?

Sinclair's lab published the foundational paper in 2003 showing that resveratrol activates SIRT1 in yeast and extends lifespan in that model [7]. He has since acknowledged that the human evidence for lifespan extension is absent and that his personal dose of approximately 500 mg/day is speculative.

The SIRT1 Activation Debate

GlaxoSmithKline's drug development program for SIRT1 activators based partly on Sinclair's work was eventually discontinued. A 2010 Nature paper by Borra et al. Questioned whether resveratrol directly activates SIRT1 in vivo or whether the in vitro findings were artifacts of the fluorescent peptide substrates used in assays. Sinclair and colleagues published a rebuttal, and the debate continues in the primary literature [8].

Cardiovascular Signal

A 2012 meta-analysis in the American Journal of Cardiology (7 trials, N=325) found resveratrol supplementation reduced systolic blood pressure by a mean of 11.9 mmHg in hypertensive subgroups, though effects in normotensive individuals were not significant [9]. Sinclair is normotensive by his own account, so any cardiovascular benefit from resveratrol in his specific case is speculative.

Metformin: The Most Controversial Element

Metformin is FDA-approved for type 2 diabetes management. Sinclair takes it off-label for longevity purposes, a use that is not FDA-approved. He disclosed a dose of 1,000 mg/day in the "Lifespan" book and has since repeated this figure on multiple podcasts, adding that he skips the dose on days he exercises because metformin may blunt the adaptive response to physical training.

Observational and Trial Evidence

Observational data from a 2014 BMJ study (N=78,241 metformin-treated diabetic patients vs. Matched non-diabetic controls) found that metformin-treated patients had lower all-cause mortality than the non-diabetic comparator group, a finding that generated significant interest in metformin as a geroprotective agent [10]. The TAME (Targeting Aging with Metformin) trial, a landmark NIH-funded multi-site study, is currently enrolling approximately 3,000 adults aged 65 to 79 to test whether metformin delays the onset of age-related diseases. Results are expected around 2026 [11].

The Exercise Interference Concern

A 2019 Cell Metabolism study (N=53 sedentary older adults) randomized participants to metformin 1,500 mg/day or placebo during a 12-week aerobic exercise program. Metformin blunted improvements in cardiorespiratory fitness (VO2 peak) and skeletal muscle mitochondrial respiration compared with placebo, though body composition changes were similar [12]. This finding is the direct basis for Sinclair's practice of skipping metformin on exercise days, a point he made explicitly on the Huberman Lab podcast.

Prescribing Reality

Metformin requires a prescription in the United States. Physicians vary widely in their willingness to prescribe it off-label for longevity. The American Diabetes Association 2024 Standards of Care do not endorse off-label metformin for anti-aging purposes outside clinical trial contexts [13].

Quercetin and Fisetin: Senolytic Candidates

Sinclair has mentioned taking quercetin, a flavonoid with putative senolytic (senescent-cell-clearing) activity, in combination with dasatinib in some discussions, though he has been less specific about the quercetin/fisetin element than about NMN or metformin. The senolytic hypothesis holds that clearing senescent cells reduces the secretion of the senescence-associated secretory phenotype (SASP), a cocktail of pro-inflammatory cytokines.

Clinical Data So Far

A 2019 pilot clinical trial published in EBioMedicine (N=14 patients with idiopathic pulmonary fibrosis) used dasatinib 100 mg plus quercetin 1,000 mg for 3 days, repeated after 3 weeks. The regimen reduced circulating senescent cell burden and improved physical function scores, though the small sample size limits conclusions [14]. Fisetin, a related flavonoid, showed senolytic activity in a 2018 EBioMedicine paper from the Mayo Clinic group, primarily in mouse models, with a human pilot currently registered at ClinicalTrials.gov [15].

Sinclair has specifically said his personal use of dasatinib is infrequent and uncertain. This element of the protocol should be treated as inference, not confirmed disclosure.

Rapamycin: The Most Potent mTOR Inhibitor He Has Discussed

Sinclair has said publicly that he has tried rapamycin, an mTOR inhibitor and FDA-approved immunosuppressant. He has not committed to a regular dose or schedule publicly, so this element is labeled as disclosed-but-unquantified. Rapamycin extended median lifespan by 9% to 14% in mice even when started late in life, in the landmark ITP (Interventions Testing Program) studies published in Nature [16].

Risk Profile in Healthy Adults

Rapamycin at standard immunosuppressive doses (1 to 5 mg/day) raises infection risk and may impair wound healing. A 2014 Science Translational Medicine study (N=218 elderly adults, rapamycin analog everolimus 0.5 mg/day for 6 weeks) found improved influenza vaccine response by 20%, suggesting that at low intermittent doses it might enhance rather than suppress immune function in older adults [17]. The dose and schedule matter enormously. Off-label use without physician supervision carries real risk.

Diet: Plant-Forward, Time-Restricted, and Low in Red Meat

Sinclair has described his diet as largely plant-based with minimal red meat. He typically skips breakfast and often lunch, putting him in a de facto one-meal-a-day or time-restricted eating pattern. He cites intermittent fasting as a SIRT1 and AMPK activator.

Protein Restriction and mTOR

One consistent theme in Sinclair's public statements is avoiding excess animal protein, specifically to keep mTOR activity low. High dietary leucine (found in red meat and dairy) is one of the strongest mTOR activators. A 2014 Cell Metabolism study by Levine et al. (N=6,381) found that protein intake <10% of calories in adults aged 50 to 65 was associated with a 75% reduction in all-cause cancer mortality over 18 years compared with high-protein intake (>20% of calories) [18]. The association reversed in adults over 65, complicating straightforward recommendations.

Caloric Restriction Mimicry

Sinclair views NMN, resveratrol, and fasting as collectively mimicking the sirtuin-activating effects of caloric restriction without requiring sustained caloric deficit. The CALERIE trial (N=218 adults, 25% caloric restriction for 2 years) showed improvements in cardiometabolic risk markers, including a 4.5 mmHg drop in systolic blood pressure and reduced LDL cholesterol, published in JAMA Internal Medicine [19].

Exercise Protocol: High-Intensity and Resistance-Based

Sinclair has described doing resistance training and high-intensity interval training (HIIT) several times per week. He avoids steady-state moderate cardio as his primary modality, based on the view that higher-intensity bouts produce greater AMPK and sirtuin activation.

HIIT and NAD+ Metabolism

A 2020 Cell Metabolism study (N=72 adults stratified by age) found that HIIT training increased skeletal muscle NAD+ levels and mitochondrial capacity more than resistance training or combined training in older adults [20]. This is one reason Sinclair prioritizes intensity over volume.

Sauna and Cold Exposure

Sinclair has mentioned regular sauna use and cold showers or ice baths. These are consistent with hormesis theory: brief physiological stress activates protective pathways including heat shock proteins and AMPK. A prospective Finnish cohort study (N=2,315 men, 20-year follow-up) published in JAMA Internal Medicine found that sauna use 4 to 7 times per week was associated with a 40% lower risk of all-cause mortality compared with once weekly [21].

Cold exposure activates brown adipose tissue and may improve insulin sensitivity, though the longevity evidence in humans is far more limited than the sauna data.

Vitamin D3, K2, and Aspirin: The Supporting Cast

Sinclair has mentioned taking vitamin D3 (typically 4,000 to 5,000 IU/day), vitamin K2, and low-dose aspirin in various podcast appearances, though with less emphasis than NMN or metformin.

Vitamin D Evidence

A 2022 meta-analysis in JAMA Network Open (27 trials, N=57,066) found that vitamin D supplementation reduced cancer mortality by 13% (RR 0.87, 95% CI 0.79 to 0.96) but did not significantly reduce cardiovascular mortality [22]. The VITAL trial (N=25,871) published in NEJM found vitamin D3 2,000 IU/day did not reduce cardiovascular events or cancer incidence, though a subsequent analysis showed reduced advanced cancer incidence in those who took the supplement for at least 2 years [23].

Low-Dose Aspirin

The ASPREE trial (N=19,114 adults aged >70, aspirin 100 mg/day) published in NEJM found no reduction in cardiovascular events and a higher rate of major hemorrhage, leading most U.S. Guidelines to advise against initiating aspirin for primary prevention in older adults [24]. Sinclair's inclusion of aspirin represents an area where his practice diverges from current guideline consensus.

Sleep and Stress Reduction

Sinclair has been explicit that sleep is the most important longevity intervention he practices. He targets 7 to 8 hours per night and uses a continuous glucose monitor and a fitness tracker to monitor sleep quality. A 2021 Nature Communications study (N=7,959) found that sleeping 6 hours or fewer at age 50 was associated with a 30% higher risk of dementia compared with sleeping 7 hours [25].

Epigenetic Age Testing: How Sinclair Tracks Progress

Sinclair has publicly stated his epigenetic (biological) age tested younger than his chronological age using methylation-based clocks, though he has not published these results in a peer-reviewed format. The Horvath clock and newer clocks such as DunedinPACE are increasingly used in longevity research. A 2022 Nature Aging paper validated DunedinPACE as a predictor of aging-related disease across multiple cohorts [26]. Self-reported biological age data from individuals outside controlled trials should be interpreted with caution.

The table below summarizes each element of Sinclair's self-reported protocol, its disclosure status, the primary evidence base, and the overall evidence grade.

| Compound or Practice | Disclosed Dose | Disclosure Source | Highest-Quality Human Evidence | Evidence Grade | |---|---|---|---|---| | NMN | 1,000 mg/day | "Lifespan" book, multiple podcasts | Yoshino et al. 2021, Science (N=25) [4] | Preliminary | | Resveratrol | ~500 mg/day in yogurt | Lex Fridman ep. 189 | Multiple small RCTs; bioavailability concerns | Mixed | | Metformin | 1,000 mg/day (skip on exercise days) | "Lifespan" book, Huberman Lab podcast | TAME trial ongoing; BMJ observational 2014 [10] | Promising, trial pending | | Quercetin | Unspecified | Lifespan podcast | EBioMedicine 2019, N=14 [14] | Very early | | Rapamycin | Unspecified, intermittent | Multiple podcasts | ITP mouse data; everolimus human pilot [17] | Preclinical + 1 human pilot | | Vitamin D3 | 4,000 to 5,000 IU/day | Various podcasts | VITAL NEJM; JAMA Network Open meta-analysis [23] | Moderate (cancer mortality signal) | | HIIT | Several times per week | Multiple interviews | Cell Metabolism 2020 [20] | Strong (fitness outcomes) | | Time-restricted eating | One meal per day tendency | "Lifespan" book | CALERIE trial [19] | Moderate | | Sauna | Regular use | Various podcasts | JAMA Intern Med Finnish cohort [21] | Moderate (observational) | | Low-dose aspirin | Unspecified | Various podcasts | ASPREE NEJM [24] | Conflicts with guidelines |

What Clinicians and Researchers Say About the Protocol

Sinclair's protocol has been critiqued and endorsed by various researchers. His Harvard colleague and aging researcher Dr. Vadim Gladyshev told Nature in 2023 that "the challenge with self-experimentation is that without controls, you cannot separate the intervention effect from regression to the mean or placebo effects." This applies directly to Sinclair's publicly reported biological age improvements.

The Endocrine Society's 2023 position statement on supplements and healthy aging states: "There is currently insufficient evidence to recommend NMN, NR, or resveratrol supplements for longevity purposes in otherwise healthy adults outside of clinical trials" [27]. This reflects the gap between the mechanistic animal-model rationale that underlies Sinclair's choices and the human randomized trial data that guidelines require.

Practical Considerations for Patients Interested in This Protocol

Several elements of Sinclair's protocol are accessible without a prescription (NMN, resveratrol, quercetin, vitamin D3, fisetin). Others require physician involvement. Metformin requires a prescription. Rapamycin requires a prescription and carries an FDA indication for organ transplant rejection and renal angiomyolipoma, not longevity.

Off-label prescribing of metformin for longevity is legal but not guideline-supported. Patients interested in this approach should discuss it with a physician who is familiar with the TAME trial rationale, can monitor kidney function (metformin is contraindicated in eGFR <30 mL/min/1.73 m2), and can evaluate individual cardiovascular risk before adding or removing aspirin.

The NMN and resveratrol elements carry no known serious safety signals at the doses Sinclair describes, though the FDA issued a letter in 2022 stating NMN could not be marketed as a dietary supplement because it had been authorized for investigation as a new drug [28]. The regulatory status of NMN in the United States remained contested as of the date of this publication.

Before adopting any element of this protocol, patients should obtain a baseline metabolic panel, HbA1c, kidney function, and a 25-hydroxyvitamin D level. These four tests provide the minimum data needed for a physician to assess safety and monitor for adverse effects.